Nutex Health Q2 Revenue Misses Estimates, Swings to Profit on Cost Cuts
NUTX has more than doubled off its 52-week low of $77.21.
Summary
Nutex Health reported Q2 revenue of $210.75M, down 14% YoY and below the $215.03M consensus, driven by the absence of a prior-year benefit from early-stage IDR process improvements. The company swung to a net profit from a loss, helped by lower contract services expenses tied to a retroactive HaloMD amendment and reduced CMS fees. Total hospital visits rose 9.6%, and management expects a 25-30% reduction in normalized contract services costs going forward, with plans to open three new hospitals this year. The revenue miss and reliance on cost-cutting for profitability may pressure the stock, despite the positive volume trend and cost outlook.
At the time of this announcement, NUTX was trading at $165.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $77.21 to $204.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.